Gene Therapy for Acquired and Genetic Cholestasis

Area of Science:

• Hepatology
• Gene Therapy
• Molecular Medicine

Background:

• Cholestatic diseases result from impaired hepatobiliary circulation transporters.
• Current pharmacological treatments are not curative, and liver transplantation has significant drawbacks.
• Gene therapy presents a potential novel therapeutic strategy for cholestatic conditions.

Purpose of the Study:

• To explore the potential of liver-directed gene therapy for treating cholestatic diseases.
• To review preclinical findings supporting gene therapy in animal models of cholestasis.
• To identify challenges and opportunities for clinical translation of gene therapy for cholestasis.

Main Methods:

• Review of preclinical gene therapy studies in animal models of acquired and genetic cholestasis.
• Analysis of gene delivery strategies using viral and non-viral vectors.
• Evaluation of therapeutic effects, including reduction of apoptosis/fibrosis and improvement of bile flow.

Main Results:

• Preclinical studies demonstrate therapeutic effects of gene therapy in rodent models of cholestasis.
• Gene delivery targeting apoptosis, fibrosis, or bile flow improvement showed positive outcomes.
• Successful application in mouse models of progressive familial intrahepatic cholestasis (PFIC3) using gene supplementation.

Conclusions:

• Liver-directed gene therapy is a promising therapeutic avenue for cholestatic diseases.
• Preclinical data support its efficacy in improving liver function and reducing disease pathology.
• Further research is needed to overcome challenges for clinical application in diverse cholestatic conditions.